Sign Out
Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A β-hemolytic streptococci), and M. catarrhalis.
Lower respiratory tract infections, including pneumonia, caused by S. pneumoniae, H. influenzae, S. pyogenes (group A β-hemolytic streptococci), and M. catarrhalis.
Upper respiratory infections, including pharyngitis and tonsillitis, caused by S. pyogenes (group A β-hemolytic streptococci), and M. catarrhalis. Sinusitis.
Note: Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Amoxicillin has been recommended by the American Heart Association as the standard regimen for the prophylaxis of bacterial endocarditis for dental, oral, and upper respiratory tract procedures, with penicillin V a rational and acceptable alternative in the prophylaxis against α-hemolytic streptococcal bacteremia in this setting. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of either rheumatic fever or bacterial endocarditis are not available at present.
Urinary tract infections, including pyelonephritis and cystitis, caused by E. coli, P. mirabilis, Klebsiella spp. and coagulase-negative staphylococci. Gonococcal urethritis.
Note: Cefaclor has been found to be effective in both acute and recurrent urinary tract infections.
Skin and skin structures infections caused by Staphylococcus aureus and S. pyogenes (group A β-hemolytic streptococci).
Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor.
Continue with Google